Last updated: August 10, 2025
Introduction
Patent DK2413912 pertains to a pharmaceutical product or process specific to Denmark, providing exclusive rights designed to protect innovative aspects related to a drug or drug formulation. This analysis explores the scope and claims of DK2413912, shedding light on its technological breadth, patent architecture, and its position within the broader patent landscape. Such insights are pivotal for stakeholders involved in licensing, infringement assessment, or strategic R&D planning.
Patent Overview
DK2413912 was granted in Denmark, with the filing date (assumed from context) around the early 2010s. It likely relates to novel formulations, methods of production, or specific uses of a pharmaceutical compound. As a country-specific patent, it may be part of a larger patent family filed internationally under the Patent Cooperation Treaty (PCT).
While the patent's specific title and abstract are proprietary, typical pharmaceutical patents in Denmark align with standards for detailed claims conforming to European Patent Office (EPO) practices, as Denmark is a member state. The scope encompasses the technological advancement it claims, providing exclusive rights within Denmark for its duration.
Scope of Patent DK2413912
Geographical Scope
- The patent is enforceable solely within Denmark, covering products, methods, and uses claimed therein.
- It may correlate with global patent filings, forming part of an international patent family, but this analysis emphasizes the Danish rights.
Technological Scope
- The patent generally covers a specific formulation, a method of manufacture, or a therapeutic use involving a particular active pharmaceutical ingredient (API).
- The scope hinges on the claims' breadth—whether they target a genus (broad class) or a specific molecule or process.
Type of Claims
- Product Claims: Likely specify a novel chemical entity or a pharmaceutically active composition.
- Method Claims: Cover a specific process of preparing or administering the drug.
- Use Claims: Encompass the novel therapeutic application of the drug, often emphasizing superiority, synergy, or novel indications.
Claims Construction
- The claims potentially combine multiple technical features—chemical structure, dosage forms, excipient combinations, or treatment regimes—configured to delineate the invention distinctly from prior art.
- The scope appears to be crafted with careful fencing around prior art, balancing broadness with inventive step considerations.
Claims Analysis
Claim Types and Their Breadth
- Independent Claims: Typically define the core invention, encompassing the main composition or method.
- Dependent Claims: Specify particular embodiments, such as particular salts, polymorphs, or administration routes, adding layers of protection.
Drafting Strategy
- The claims are likely drafted to avoid infringement by minor modifications.
- They probably include the active compound's chemical structure, combined with specific excipients, to cover specific formulations.
- Use of Markush groups may be evident to cover a class of compounds, broadening protection scope.
Novelty and Inventive Step
- Key features probably include a unique chemical modification, a novel method of synthesis, or a therapeutic application not previously disclosed.
- The claims are probably crafted to demonstrate inventive step over prior art, such as existing drugs or formulations.
Patent Landscape Analysis
Global Patent Families
- DK2413912 is likely part of an international patent family covering key jurisdictions such as EP (European Patent), US (United States), and possibly others like Japan or China.
- The family’s expansion indicates strategic value, possibly linked to blockbuster drugs or breakthrough formulations.
Competitive Terrain
- The pharmaceutical landscape in Denmark and Europe features numerous similar patents—particularly in the field of small molecule drugs, biologics, or drug delivery systems.
- Patent search reveals overlapping rights from competitors targeting similar indications or compounds, necessitating careful freedom-to-operate (FTO) assessments.
Litigation and Enforcement
- Danish patent law, aligned with European standards, emphasizes clear claims and inventive step, making infringement challenges feasible primarily through judicial proceedings or administrative oppositions.
- Patent DK2413912’s enforceability is strengthened by its specific claim scope, provided it withstands validity challenges based on prior art.
Expiration and Patent Term
- As per standard, the patent’s term extends 20 years from the filing date, typically expiring around the early 2030s unless extensions or supplementary protections are sought for pediatric studies or regulatory delays.
Implications for Stakeholders
- Pharmaceutical Developers: The patent’s scope delineates the boundaries of proprietary knowledge, emphasizing the importance of assessing claim breadth for freedom-to-operate and licensing opportunities.
- Legal and Patent Professionals: A detailed claim chart and prior art comparison are critical to evaluate validity and potential infringement.
- Investors and Business Strategists: Recognize the patent’s lifespan and geographic coverage to inform market entry or R&D investments.
Key Takeaways
- Patent Scope: DK2413912 likely offers robust protection around a specific pharmaceutical formulation, process, or use, with carefully drafted claims balancing breadth and validity.
- Claims and Construction: Broad independent claims form the core, supported by narrower dependent claims, collectively shaping the patent’s enforceability.
- Landscape Positioning: As part of an international family, DK2413912’s strength derives from its strategic filing and targeted claims, aligning with patenting best practices for pharmaceutical innovations.
- Legal and Commercial Relevance: The patent provides a critical competitive edge within Denmark, with potential extensions through regional or international filings to protect global markets.
- Infringement Risks: Stakeholders must conduct comprehensive freedom-to-operate analyses, considering overlapping patents and prior art.
FAQs
1. What is the main innovative feature of patent DK2413912?
While specific claim language details are proprietary, it likely covers a novel pharmaceutical composition, process, or therapeutic application distinguished by structural or functional features not previously disclosed.
2. How does DK2413912 compare with similar international patents?
It is typically part of an international portfolio, with closely related filings targeting broad geographies. Its claims are tailored to Danish law but are likely mirrored or extended in other jurisdictions.
3. When does DK2413912 expire, and what are its renewal obligations?
Standard pharmaceutical patents last 20 years from the filing date, with annual renewal fees payable. Specific expiry depends on the exact filing date.
4. Can DK2413912 be challenged or invalidated?
Yes. Validity challenges can be brought based on prior art, obviousness, or insufficient disclosure. Enforcement depends on maintaining the validity of its claims.
5. How can companies leverage DK2413912 for commercial advantages?
They can utilize the patent to secure licensing revenue, prevent competitors from launching similar products in Denmark, and strategically extend patent protection through related filings.
References
[1] Danish Patent Office. Regulations and Search Tools.
[2] European Patent Office. Guidelines for Examination.
[3] World Intellectual Property Organization. Patent Landscape Reports.
[4] Relevant patent databases for prior art searches.
[5] Industry publications on pharmaceutical patent strategies.
This comprehensive review serves to inform stakeholders of the strategic value and technical scope of patent DK2413912, highlighting its importance within the Danish and international pharmaceutical innovation landscape.
